Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cancer Neoplasms Metastatic Cancer Triple Negative Breast Cancer Gastric Cancer Cervical Cancer Ovarian Cancer Hepatocellular Carcinoma Squamous Cell Carcinoma of Head and Neck Urothelial Carcinoma Urothelial Neoplasm Non Small Cell Lung Cancer Renal Cell Carcinoma Locally Advanced Solid Tumor Locally Advanced Malignant Neoplasm Squamous Cell Carcinoma Sarcoma Merkel Cell Carcinoma Bladder Cancer Have histological or cytological evidence of a diagnosis of selected cancer types that is locally advanced and/or metastatic 1. Have the presence of evaluable disease for the Phase 1b part of the study 2. Have the presence of evaluable and measurable disease for the Phase 2a part of the study 3. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed to provide clinical benefit for their disease or patients who have refused standard treatments. 2. Cancer treatment and type Have received at least 1 but no more than 4 prior systemic therapies for locally advanced or metastatic disease (e.g., hormonal, cytotoxic, etc.) for the following cancer types, for Phase 1b Triple Negative Breast Cancer (TNBC): Must have recurrent/refractory TNBC, defined as any breast cancer that expresses less than (˂)1% estrogen receptor (ER), ˂ 1% progesterone receptor (PR), and is Human Epidermal Growth Factor Receptor 2 (Her2) negative. Must have failed at least one chemotherapy regimen Gastric Cancer: Must have failed a platinum-containing chemotherapy regime Cervical Cancer: Must have failed at least one chemotherapy regimen Ovarian Cancer: Must have failed a platinum-containing chemotherapy regimen but not be platinum refractory Hepatocellular Cell Carcinoma (HCC): May have failed unlimited liver local therapies Sarcoma: Must have failed at least one prior chemotherapy regimen Squamous Cell Carcinoma of Head and Neck (SCCHN): Must have failed a platinum-containing chemotherapy regiment. Must have failed a previous immune checkpoint inhibitor Bladder Cancer: Must have failed a platinum-containing chemotherapy regiment. Must have failed a previous immune checkpoint inhibitor  Have symptomatic central nervous system (CNS) metastasis. Patients with treated CNS metastases are eligible for this study if they are asymptomatic and off of corticosteroids for a minimum of 7 days. Patients with primary brain tumors are not eligible 2. Have a history of major organ transplant (e.g., heart, lungs, liver, and kidney) or an autologous or allogeneic hematopoietic stem cell transplant 3. Females who are pregnant or nursing 4. Have known, symptomatic acquired immuno deficiency syndrome (AIDS) or active hepatitis A, B or C 5. Previous treatment-related, severe (≥Grade 3) Adverse Event (AE) or any neurologic or ocular AE while receiving an IO agent 6. Active or prior documented autoimmune disease within the past 2 years Patients with vitiligo, Grave's disease or psoriasis not requiring systemic treatment within the past 2 years are eligible 7. Active or prior documented inflammatory bowel disease 8. History of tuberculosis, interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required corticosteroid therapy 9. Receipt of live attenuated vaccination within 28 days prior 10. Current or prior use of immunosuppressive medication within 28 days prior 11. Are currently enrolled in another clinical study of an investigational medicinal product 12. Have a second primary malignancy that may affect the interpretation of results 13. Are unwilling or unable to participate in, or do not have tissue adequate for a tumor biopsy